Literature DB >> 33755783

Simvastatin inhibits oral squamous cell carcinoma by targeting TMEM16A Ca2+-activated chloride channel.

Hechen Wang1,2, Tianyu Wang2, Zeying Zhang1, Yu Fan3, Lan Zhang4, Kuan Gao2, Shuya Luo2, Qinghuan Xiao5, Changfu Sun6.   

Abstract

PURPOSE: Ca2+-activated chloride channel TMEM16A has been found to be overexpressed in many cancers including head and neck squamous cell carcinoma (HNSCC). Nevertheless, the role of TMEM16A in oral squamous cell carcinoma (OSCC) remains unclear. Although simvastatin is known to produce anti-tumor effect, the mechanisms by which simvastatin inhibits cancer remain unclear.
METHODS: In this study, we explored the role of TMEM16A expression in human OSCC tissues using both TCGA dataset and immunohistochemistry. CCK-8 assay was applied to evaluate cell proliferation. Patch clamp technique was applied to record TMEM16A Cl- currents.
RESULTS: We found that high TMEM16A expression is related with large tumor size, lymph node metastasis, and poor clinical outcome in patients with OSCC. In addition, TMEM16A overexpression could promote cell proliferation, and inhibition of TMEM16A channel activities could suppress cell proliferation in OSCC cells. Furthermore, simvastatin could suppress TMEM16A channel activities, and inhibited cell proliferation in OSCC cells via TMEM16A.
CONCLUSION: Our findings identify a novel anti-tumor mechanism of simvastatin by targeting TMEM16A. Simvastatin may represent an innovative strategy for treating OSCC with high TMEM16A expression.

Entities:  

Keywords:  Ca2+-activated chloride channel; Oral squamous cell carcinoma; Simvastatin; TMEM16A

Year:  2021        PMID: 33755783     DOI: 10.1007/s00432-021-03575-w

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  48 in total

1.  Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling.

Authors:  Adrian Britschgi; Anke Bill; Heike Brinkhaus; Christopher Rothwell; Ieuan Clay; Stephan Duss; Michael Rebhan; Pichai Raman; Chantale T Guy; Kristie Wetzel; Elizabeth George; M Oana Popa; Sarah Lilley; Hedaythul Choudhury; Martin Gosling; Louis Wang; Stephanie Fitzgerald; Jason Borawski; Jonathan Baffoe; Mark Labow; L Alex Gaither; Mohamed Bentires-Alj
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

2.  Lovastatin induces a pronounced differentiation response in acute myeloid leukemias.

Authors:  J Dimitroulakos; S Thai; G H Wasfy; D W Hedley; M D Minden; L Z Penn
Journal:  Leuk Lymphoma       Date:  2000-12

Review 3.  Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma.

Authors:  Andre Cassell; Jennifer R Grandis
Journal:  Expert Opin Investig Drugs       Date:  2010-06       Impact factor: 6.206

4.  Anoctamin 1 (TMEM16A) is essential for testosterone-induced prostate hyperplasia.

Authors:  Joo Young Cha; Jungwon Wee; Jooyoung Jung; Yongwoo Jang; Byeongjun Lee; Gyu-Sang Hong; Beom Chul Chang; Yoon-La Choi; Young Kee Shin; Hye-Young Min; Ho-Young Lee; Tae-Young Na; Mi-Ock Lee; Uhtaek Oh
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-07       Impact factor: 11.205

5.  ANO1 amplification and expression in HNSCC with a high propensity for future distant metastasis and its functions in HNSCC cell lines.

Authors:  C Ayoub; C Wasylyk; Y Li; E Thomas; L Marisa; A Robé; M Roux; J Abecassis; A de Reyniès; B Wasylyk
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

6.  ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer.

Authors:  Anke Bill; Abraham Gutierrez; Sucheta Kulkarni; Carolyn Kemp; Debora Bonenfant; Hans Voshol; Umamaheswar Duvvuri; L Alex Gaither
Journal:  Oncotarget       Date:  2015-04-20

7.  TMEM16A/ANO1 is differentially expressed in HPV-negative versus HPV-positive head and neck squamous cell carcinoma through promoter methylation.

Authors:  Ronak Dixit; Carolyn Kemp; Scott Kulich; Raja Seethala; Simion Chiosea; Shizhang Ling; Patrick K Ha; Umamaheswar Duvvuri
Journal:  Sci Rep       Date:  2015-11-13       Impact factor: 4.379

8.  Small molecule-facilitated degradation of ANO1 protein: a new targeting approach for anticancer therapeutics.

Authors:  Anke Bill; Michelle Lynn Hall; Jason Borawski; Catherine Hodgson; Jeremy Jenkins; Philippe Piechon; Oana Popa; Christopher Rothwell; Pamela Tranter; Scott Tria; Trixie Wagner; Lewis Whitehead; L Alex Gaither
Journal:  J Biol Chem       Date:  2014-03-05       Impact factor: 5.157

9.  Simvastatin Enhances the Effects of Radiotherapy and Cetuximab on a Cell Line (FaDu) Derived from a Squamous Cell Carcinoma of Head and Neck.

Authors:  Lara I de Llobet; Marta Baro; Ricard Mesia; Josep Balart
Journal:  Transl Oncol       Date:  2014-03-05       Impact factor: 4.243

10.  Knockdown of TMEM16A suppressed MAPK and inhibited cell proliferation and migration in hepatocellular carcinoma.

Authors:  Liang Deng; Jihong Yang; Hongwu Chen; Bo Ma; Kangming Pan; Caikun Su; Fengfeng Xu; Jihong Zhang
Journal:  Onco Targets Ther       Date:  2016-01-14       Impact factor: 4.147

View more
  2 in total

Review 1.  TMEM16A as a potential treatment target for head and neck cancer.

Authors:  Kohei Okuyama; Souichi Yanamoto
Journal:  J Exp Clin Cancer Res       Date:  2022-06-07

2.  Identification and validation of a signature involving voltage-gated chloride ion channel genes for prediction of prostate cancer recurrence.

Authors:  Yong Luo; Xiaopeng Liu; Xiaoxiao Li; Weide Zhong; Jingbo Lin; Qingbiao Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-30       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.